Johanna Friedl-Naderer - Feb 22, 2023 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Role
EVP & Chief Operating Officer
Signature
/s/ Howard Horn, Attorney-in-Fact
Stock symbol
VIR
Transactions as of
Feb 22, 2023
Transactions value $
$0
Form type
4
Date filed
2/24/2023, 07:27 PM
Previous filing
Mar 8, 2022
Next filing
Mar 7, 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VIR Common Stock Award $0 +60K +66.67% $0.00 150K Feb 22, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VIR Stock Option (Right to Buy) Award $0 +70K $0.00 70K Feb 22, 2023 Common Stock 70K $27.01 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan.
F2 25% of the shares subject to the stock option vest and become exercisable on February 22, 2024, and the remainder vest in 36 equal monthly installments thereafter.